

CITATION REPORT

List of articles citing

Myeloid-derived suppressor cells in cancer patients: a clinical perspective

DOI: 10.1097/cji.ob013e318242169f
Journal of Immunotherapy, 2012, 35, 107-15.

Source: <https://exaly.com/paper-pdf/52968616/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
188	Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention. 2012 , 2012, 160724		37
187	Characterization of iNOS(+) Neutrophil-like ring cell in tumor-bearing mice. 2012 , 10, 152		12
186	Highlights on molecular mechanisms of MDSC-mediated immune suppression: paving the way for new working hypotheses. 2012 , 41, 722-37		29
185	Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. 2012 , 12, 1597-611		94
184	AdCD40L--crossing the valley of death?. 2012 , 31, 289-98		14
183	Cancer as an immune-mediated disease. 2012 , 1, 1-6		22
182	Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. 2013 , 11, 62		60
181	Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. 2013 , 1, 10		215
180	Protumor and antitumor functions of neutrophil granulocytes. 2013 , 35, 163-76		103
179	Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma. 2013 , 15, 1400-9		101
178	JAK/STAT Signaling in Myeloid Cells: Targets for Cancer Immunotherapy. 2013 , 435-449		
177	Tumor-induced Myeloid-derived Suppressor Cells. 2013 , 473-496		2
176	Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. 2013 , 12, 1461-70		170
175	Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly. 2013 , 57, 172-84		80
174	Mesenchymal stem cells tune the development of monocyte-derived dendritic cells toward a myeloid-derived suppressive phenotype through growth-regulated oncogene chemokines. <i>Journal of Immunology</i> , 2013 , 190, 5065-77	5.3	72
173	History of myeloid-derived suppressor cells. <i>Nature Reviews Cancer</i> , 2013 , 13, 739-52	31.3	793
172	Clinical significance and functional studies of myeloid-derived suppressor cells in chronic hepatitis C patients. 2013 , 33, 798-808		73

171	Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. 2013 , 121, 2975-87		268
170	A role for HMGB1, HSP60 and Myd88 in growth of murine mammary carcinoma in vitro. <i>Cellular Immunology</i> , 2013 , 282, 136-45	4-4	17
169	The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: cousins, siblings or twins?. 2013 , 23, 171-82		114
168	Tumor microenvironment and myeloid-derived suppressor cells. 2013 , 6, 169-77		90
167	The Tumor Immunoenvironment. 2013 ,		3
166	Influence of human immune cells on cancer: studies at the University of Colorado. 2013 , 55, 22-33		11
165	Myeloid-derived suppressor cells and the efficacy of CD8 T-cell immunotherapy. 2013 , 2, e22764		4
164	Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients. 2013 , 2, e23288		19
163	Monitoring regulatory immune responses in tumor immunotherapy clinical trials. <i>Frontiers in Oncology</i> , 2013 , 3, 109	5-3	15
162	The role of the immune response in merkel cell carcinoma. <i>Cancers</i> , 2013 , 5, 234-54	6.6	28
161	MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. 2013 , 6, 18-26		166
160	Expansion of monocytic myeloid-derived suppressor cells dampens T cell function in HIV-1-seropositive individuals. 2013 , 87, 1477-90		128
159	Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. <i>Frontiers in Oncology</i> , 2013 , 3, 49	5-3	114
158	Trial Watch: Adoptive cell transfer for anticancer immunotherapy. 2013 , 2, e24238		43
157	Inhibition of endogenous activated protein C attenuates experimental autoimmune encephalomyelitis by inducing myeloid-derived suppressor cells. <i>Journal of Immunology</i> , 2013 , 191, 3764-77	5-3	24
156	MIF: metastasis/MDSC-inducing factor?. 2013 , 2, e23337		16
155	Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. <i>Journal of Immunology</i> , 2013 , 190, 2464-71	5-3	156
154	A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model. 2013 , 15, R79		99

153	Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. 2013 , 4, 3-11		80
152	Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. <i>PLoS ONE</i> , 2013 , 8, e57114	3.7	183
151	Interleukin-6 mediates epithelial-stromal interactions and promotes gastric tumorigenesis. <i>PLoS ONE</i> , 2013 , 8, e60914	3.7	56
150	Expression of the B-cell receptor component CD79a on immature myeloid cells contributes to their tumor promoting effects. <i>PLoS ONE</i> , 2013 , 8, e76115	3.7	27
149	The immunologic basis for severe neonatal herpes disease and potential strategies for therapeutic intervention. 2013 , 2013, 369172		33
148	Cellular Composition of the Tumor Microenvironment. 2013 , e91-e97		17
147	Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients. <i>PLoS ONE</i> , 2014 , 9, e101848	3.7	55
146	Myeloid Derived Suppressor Cells: Fuel the Fire. 2014 , 3, e123		10
145	Blockade of Fas signaling in breast cancer cells suppresses tumor growth and metastasis via disruption of Fas signaling-initiated cancer-related inflammation. 2014 , 289, 11522-11535		21
144	Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination. 2014 , 10, 3251-60		33
143	Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKC β abundance. 2014 , 7, ra16		34
142	Advances in Tumor Immunology and Immunotherapy. 2014 ,		0
141	Nano-Oncologicals. <i>Advances in Delivery Science and Technology</i> , 2014 ,		4
140	Nanotechnology Approaches for Cancer Immunotherapy and Immunomodulation. <i>Advances in Delivery Science and Technology</i> , 2014 , 215-242		0
139	Metabolic control of tumour progression and antitumour immunity. <i>Current Opinion in Oncology</i> , 2014 , 26, 92-9	4.2	16
138	Immunoguiding, the Final Frontier in the Immunotherapy of Cancer. 2014 , 37-51		
137	Is Infant Immunity Actively Suppressed or Immature?. 2014 , 2014, 1-9		25
136	Macrophages are more potent immune suppressors ex vivo than immature myeloid-derived suppressor cells induced by metastatic murine mammary carcinomas. <i>Journal of Immunology</i> , 2014 , 192, 512-22	5.3	26

135	Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy. 2014 , 31, 185-98		18
134	Myeloid-derived suppressor cell function is diminished in aspirin-triggered allergic airway hyperresponsiveness in mice. 2014 , 134, 1163-74.e16		38
133	Tumor-associated macrophages: from mechanisms to therapy. 2014 , 41, 49-61		2228
132	Trial Watch: Adoptive cell transfer for anticancer immunotherapy. 2014 , 3, e28344		30
131	Myeloid-derived suppressor cell heterogeneity in human cancers. 2014 , 1319, 47-65		280
130	Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion. <i>European Journal of Immunology</i> , 2014 , 44, 3307-19	6.1	81
129	Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. 2014 , 63, 1769-81		202
128	Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. 2014 , 41, 174-84		128
127	Tumor-Induced Immune Suppression. 2014 ,		1
126	Myeloid derived suppressor cells in chronic myeloid leukemia. <i>Frontiers in Oncology</i> , 2015 , 5, 107	5.3	26
125	Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. 2015 , 128, 95-139		319
124	Myeloid-derived suppressor cells: their role in the pathophysiology of hematologic malignancies and potential as therapeutic targets. 2015 , 56, 2251-63		20
123	Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model. 2015 , 17, 978-91		56
122	Interferon alpha-induced reduction in the values of myeloid-derived suppressor cells in melanoma patients. 2015 , 72, 342-9		3
121	Effect of TLR agonists on the differentiation and function of human monocytic myeloid-derived suppressor cells. <i>Journal of Immunology</i> , 2015 , 194, 4215-21	5.3	45
120	In the hunt for therapeutic targets: mimicking the growth, metastasis, and stromal associations of early-stage lung cancer using a novel orthotopic animal model. 2015 , 10, 46-58		8
119	A subpopulation that may correspond to granulocytic myeloid-derived suppressor cells reflects the clinical stage and progression of cutaneous melanoma. 2016 , 28, 87-97		17
118	Monocytic MDSCs regulate macrophage-mediated xenogenic cytotoxicity. 2015 , 33, 140-5		13

117	Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small-cell lung cancer. 2015 , 180, 467-74		26
116	Trial Watch: Adoptive cell transfer for oncological indications. 2015 , 4, e1046673		22
115	Myeloid-derived cells in tumors: effects of radiation. 2015 , 25, 18-27		91
114	Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. <i>Clinical Cancer Research</i> , 2015 , 21, 39-48	12.9	167
113	Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. 2015 , 33, 540-9		1155
112	MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer. <i>Oncotarget</i> , 2016 , 7, 4760-9	3.3	43
111	Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC). <i>Oncotarget</i> , 2016 , 7, 85764-85775	3.3	56
110	Current understanding of the tumor microenvironment of laryngeal dysplasia and progression to invasive cancer. 2016 , 24, 121-7		16
109	CD33(+)/HLA-DR(neg) and CD33(+)/HLA-DR(+/-) Cells: Rare Populations in the Human Decidua with Characteristics of MDSC. 2016 , 75, 539-56		17
108	Clinical Significance of Myeloid-Derived Suppressor Cells in Human Immunodeficiency Virus-1/Hepatitis C Virus-coinfected Patients. 2016 , 83, 438-44		8
107	Tumor-Induced Myeloid-Derived Suppressor Cells. 2016 , 4,		21
106	Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 983-94	7.4	14
105	Myeloid cells as orchestrators of the tumor microenvironment: novel targets for nanoparticulate cancer therapy. 2016 , 11, 2735-2751		16
104	L-Arginine supplementation inhibits the growth of breast cancer by enhancing innate and adaptive immune responses mediated by suppression of MDSCs in vivo. <i>BMC Cancer</i> , 2016 , 16, 343	4.8	45
103	Inhibiting MDSC differentiation from bone marrow with phytochemical polyacetylenes drastically impairs tumor metastasis. <i>Scientific Reports</i> , 2016 , 6, 36663	4.9	16
102	Immune Suppressive Myeloid-Derived Suppressor Cells in Cancer. 2016 , 512-525		2
101	The Biodistribution and Immune Suppressive Effects of Breast Cancer-Derived Exosomes. 2016 , 76, 6816-6827		162
100	Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent. 2016 , 26, 381-9		39

99	Myeloid cells in the tumor microenvironment: Role of adenosine. 2016 , 5, e1108515		27
98	The emerging role of myeloid-derived suppressor cells in lung diseases. 2016 , 47, 967-77		31
97	Aminoacyl-tRNA synthetase-interacting multifunctional protein 1 suppresses tumor growth in breast cancer-bearing mice by negatively regulating myeloid-derived suppressor cell functions. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 61-72	7.4	12
96	Myeloid-derived suppressor cells (MDSC) facilitate distant metastasis of malignancies by shielding circulating tumor cells (CTC) from immune surveillance. 2016 , 87, 34-9		28
95	Cisplatin selectively downregulated the frequency and immunoinhibitory function of myeloid-derived suppressor cells in a murine B16 melanoma model. 2016 , 64, 160-70		34
94	MDSCs in cancer: Conceiving new prognostic and therapeutic targets. 2016 , 1865, 35-48		51
93	Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment. 2016 , 380, 253-6		56
92	Tolerance and immune suppression in the tumor microenvironment. <i>Cellular Immunology</i> , 2016 , 299, 23-9	4.4	33
91	Personalized approaches to active immunotherapy in cancer. 2016 , 1865, 72-82		30
90	Immune regulatory network in successful pregnancy and reproductive failures. 2017 , 88, 61-73		69
89	Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study. 2017 , 19, 500-513		42
88	Metchnikoff's Legacy: Tissue Phagocytes and Functions. <i>European Journal of Immunology</i> , 2017 , 47, 10-13	1	1
87	Expansion and activation of granulocytic, myeloid-derived suppressor cells in childhood precursor B cell acute lymphoblastic leukemia. <i>Journal of Leukocyte Biology</i> , 2017 , 102, 449-458	6.5	18
86	Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. <i>Pharmacology & Therapeutics</i> , 2017 , 179, 171-187	13.9	97
85	Introducing ECI 2018. <i>European Journal of Immunology</i> , 2017 , 47, 12-13	6.1	0
84	Establishing High Dimensional Immune Signatures from Peripheral Blood via Mass Cytometry in a Discovery Cohort of Stage IV Melanoma Patients. <i>Journal of Immunology</i> , 2017 , 198, 927-936	5.3	27
83	Impaired Transmigration of Myeloid-Derived Suppressor Cells across Human Sinusoidal Endothelium Is Associated with Decreased Expression of CD13. <i>Journal of Immunology</i> , 2017 , 199, 1672-1681	5.3	7
82	Regulatory myeloid cells: an underexplored continent in B-cell lymphomas. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 1103-1111	7.4	15

81	Granulocytic Myeloid-Derived Suppressor Cells Increased in Early Phases of Primary HIV Infection Depending on TRAIL Plasma Level. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 74, 575-582	3.1	17
80	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. 2017 , 5, 44		139
79	Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells. <i>Clinical Cancer Research</i> , 2017 , 23, 587-599	13.9	148
78	Pivotal regulators of tissue homeostasis and cancer: macrophages. <i>Experimental Hematology and Oncology</i> , 2017 , 6, 23	7.8	23
77	Neutrophil-lymphocyte ratio complements volumetric staging as prognostic factor in patients treated with definitive radiotherapy for oropharyngeal cancer. <i>BMC Cancer</i> , 2017 , 17, 643	4.8	8
76	Myeloid-derived suppressor cells in lymphoma: The good, the bad and the ugly. <i>Blood Reviews</i> , 2018 , 32, 490-498	11.1	18
75	Chemotherapy alters the increased numbers of myeloid-derived suppressor and regulatory T cells in children with acute lymphoblastic leukemia. <i>Immunopharmacology and Immunotoxicology</i> , 2018 , 40, 158-167	3.2	20
74	The microbiome and cancer. <i>Journal of Pathology</i> , 2018 , 244, 667-676	9.4	98
73	Loss of Myeloid-Specific TGF- β Signaling Decreases CTHRC1 to Downregulate bFGF and the Development of H1993-Induced Osteolytic Bone Lesions. <i>Cancers</i> , 2018 , 10,	6.6	8
72	Blood-based analyses of cancer: Circulating myeloid-derived suppressor cells - is a new era coming?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2018 , 55, 376-407	9.4	9
71	Circulating and tumor-infiltrating myeloid-derived suppressor cells in cervical carcinoma patients. <i>Oncology Letters</i> , 2018 , 15, 9507-9515	2.6	18
70	Resveratrol ameliorates Lewis lung carcinoma-bearing mice development, decreases granulocytic myeloid-derived suppressor cell accumulation and impairs its suppressive ability. <i>Cancer Science</i> , 2018 , 109, 2677-2686	6.9	21
69	Factors Influencing the Differentiation of Human Monocytic Myeloid-Derived Suppressor Cells Into Inflammatory Macrophages. <i>Frontiers in Immunology</i> , 2018 , 9, 608	8.4	25
68	Myeloid-Derived Suppressor Cells Are Regulated by Estradiol and Are a Predictive Marker for IVF Outcome. <i>Frontiers in Endocrinology</i> , 2019 , 10, 521	5.7	7
67	The clinical significance of myeloid-derived suppressor cells in dengue fever patients. <i>BMC Infectious Diseases</i> , 2019 , 19, 926	4	7
66	Immune control by amino acid catabolism during tumorigenesis and therapy. <i>Nature Reviews Cancer</i> , 2019 , 19, 162-175	31.3	95
65	Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: a meta-analysis. <i>BMC Cancer</i> , 2019 , 19, 338	4.8	10
64	Pathogenicity and Drug Resistance of Human Pathogens. 2019 ,		1

63	Racial Differences in Immunological Landscape Modifiers Contributing to Disparity in Prostate Cancer. <i>Cancers</i> , 2019 , 11,	6.6	13
62	Tumor Microenvironment in T-Cell Lymphomas. <i>Cancer Treatment and Research</i> , 2019 , 176, 69-82	3.5	5
61	Uterine Cervical Cancer. 2019 ,		1
60	Immunotherapy for Precancerous Lesions of the Uterine Cervix. 2019 , 107-140		
59	Myeloid-derived suppressor cells and tumor: Current knowledge and future perspectives. <i>Journal of Cellular Physiology</i> , 2019 , 234, 9966-9981	7	29
58	Synergistic effect of adoptive immunotherapy and docetaxel inhibits tumor growth in a mouse model. <i>Cellular Immunology</i> , 2020 , 348, 104036	4.4	4
57	Nanoparticles decorated with granulocyte-colony stimulating factor for targeting myeloid cells. <i>Nanoscale</i> , 2020 , 12, 2752-2763	7.7	4
56	Role of Microenvironment in Non-Hodgkin Lymphoma: Understanding the Composition and Biology. <i>Cancer Journal (Sudbury, Mass)</i> , 2020 , 26, 206-216	2.2	4
55	The role of myeloid-derived suppressor cells in hematologic malignancies. <i>Current Opinion in Oncology</i> , 2020 , 32, 518-526	4.2	4
54	Explicating the Pivotal Pathogenic, Diagnostic, and Therapeutic Biomarker Potentials of Myeloid-Derived Suppressor Cells in Glioblastoma. <i>Disease Markers</i> , 2020 , 2020, 8844313	3.2	5
53	Hepatobiliary malignancies have distinct peripheral myeloid-derived suppressor cell signatures and tumor myeloid cell profiles. <i>Scientific Reports</i> , 2020 , 10, 18848	4.9	2
52	Commentary on characterization of urinary microbiome in patients with bladder cancer: Results from a single-institution, feasibility study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 622	2.8	
51	Apolipoprotein A-I Mimetic Peptide L-4F Suppresses Granulocytic-Myeloid-Derived Suppressor Cells in Mouse Pancreatic Cancer. <i>Frontiers in Pharmacology</i> , 2020 , 11, 576	5.6	6
50	Radiation therapy and the innate immune response: Clinical implications for immunotherapy approaches. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 1726-1735	3.8	9
49	Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19). <i>Cell Death and Differentiation</i> , 2020 , 27, 3196-3207	12.7	115
48	Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects. <i>Clinical Medicine Insights: Oncology</i> , 2021 , 15, 11795549211035540	1.8	2
47	CCL25 Signaling in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2021 , 1302, 99-111	3.6	0
46	Arginine-dependent immune responses. <i>Cellular and Molecular Life Sciences</i> , 2021 , 78, 5303-5324	10.3	13

45	Inflammation and tumor progression: signaling pathways and targeted intervention. <i>Signal Transduction and Targeted Therapy</i> , 2021 , 6, 263	21	107
44	COVID-19, what could sepsis, severe acute pancreatitis, gender differences, and aging teach us?. <i>Cytokine</i> , 2021 , 148, 155628	4	3
43	High-Dimensional Phenotyping of Human Myeloid-Derived Suppressor Cells/Tumor-Associated Macrophages in Tissue by Mass Cytometry. <i>Methods in Molecular Biology</i> , 2021 , 2236, 57-66	1.4	3
42	Role of the Immunological Environment in Cancer Initiation, Development and Progression. 2013 , 1-12		1
41	Cholangiocarcinoma presents a distinct myeloid-derived suppressor cell signature compared to other hepatobiliary cancers.		1
40	Tumor-Induced Myeloid-Derived Suppressor Cells. 833-856		1
39	Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells. <i>JCI Insight</i> , 2019 , 4,	9.9	44
38	STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. <i>Journal of Clinical Investigation</i> , 2013 , 123, 1580-9	15.9	349
37	ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. <i>Journal of Clinical Investigation</i> , 2014 , 124, 2626-39	15.9	209
36	Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. <i>Journal of Clinical Investigation</i> , 2015 , 125, 3365-76	15.9	351
35	Glycan elongation beyond the mucin associated Tn antigen protects tumor cells from immune-mediated killing. <i>PLoS ONE</i> , 2013 , 8, e72413	3.7	26
34	Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma. <i>PLoS ONE</i> , 2013 , 8, e82406	3.7	18
33	Myeloid derived suppressor cells are present at high frequency in neonates and suppress in vitro T cell responses. <i>PLoS ONE</i> , 2014 , 9, e107816	3.7	57
32	Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes. <i>PLoS ONE</i> , 2015 , 10, e0131934	3.7	10
31	Ascites-derived IL-6 and IL-10 synergistically expand CD14HLA-DR myeloid-derived suppressor cells in ovarian cancer patients. <i>Oncotarget</i> , 2017 , 8, 76843-76856	3.3	53
30	CXCR2 MDSCs promote breast cancer progression by inducing EMT and activated T cell exhaustion. <i>Oncotarget</i> , 2017 , 8, 114554-114567	3.3	54
29	S100A9 MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of. <i>Oncotarget</i> , 2018 , 9, 7631-7643	3.3	17
28	Novel adherent CD11b Gr-1 tumor-infiltrating cells initiate an immunosuppressive tumor microenvironment. <i>Oncotarget</i> , 2018 , 9, 11209-11226	3.3	6

27	Perspectives of Immune Suppression in the Tumor Microenvironment Promoting Oral Malignancy. <i>Open Dentistry Journal</i> , 2018 , 12, 455-465	0.8	6
26	Dual roles of myeloid-derived suppressor cells induced by Toll-like receptor signaling in cancer. <i>Oncology Letters</i> , 2021 , 21, 149	2.6	7
25	Increased Monocytic Myeloid-Derived Suppressor Cells in Whole Blood Predict Poor Prognosis in Patients with Plasma Cell Myeloma. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
24	Daily caloric restriction limits tumor growth more effectively than caloric cycling regardless of dietary composition. <i>Nature Communications</i> , 2021 , 12, 6201	17.4	9
23	LncRNAs in tumor microenvironment: The potential target for cancer treatment with natural compounds and chemical drugs. <i>Biochemical Pharmacology</i> , 2021 , 193, 114802	6	3
22	Inflammation, Tumor Progression, and Immune Suppression. 2013 , 177-196		
21	Development of Antitumor Cellular Immunity. 2013 , 107-133		
20	Approaches to Immunologic Monitoring of Clinical Trials. 2013 , 663-694		
19	Analysis of Myeloid-Derived Suppressor Cells in Patients with Cancer. 2013 , 707-723		
18	Programming of MDSC: New Opportunities for Targeted Therapy. 2013 , 567-584		
17	Myeloid-Derived Suppressor Cells in Cancer. 2014 , 3-17		
16	Cancer Immune Modulation and Immunosuppressive Cells: Current and Future Therapeutic Approaches. <i>Advances in Delivery Science and Technology</i> , 2014 , 187-214		
15	Myeloid-Derived Suppressor Cells in Tumor-Induced T Cell Suppression and Tolerance. 2014 , 99-150		2
14	Gastrointestinal Cancer Prevention: Diet, Lifestyle, and Therapeutic Prevention. 2019 , 509-532		
13	Human Microbiome and Malignancy: Principles, Mechanisms, and Challenges. 2019 , 317-335		
12	Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells.		
11	Targeting myeloid-derived suppressor cells to attenuate vasculogenic mimicry and synergistically enhance the anti-tumor effect of PD-1 inhibitor. <i>IScience</i> , 2021 , 24, 103392	6.1	0
10	G protein signaling modulator-3: a leukocyte regulator of inflammation in health and disease. <i>American Journal of Clinical and Experimental Immunology</i> , 2014 , 3, 97-106	1.2	12

9	Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.. <i>Pharmacology & Therapeutics</i> , 2022 , 108114	13.9	2
8	Image_1.TIF. 2019 ,		
7	Image_2.TIF. 2019 ,		
6	Image_3.TIF. 2019 ,		
5	image_1.jpeg. 2018 ,		
4	Association of Systemic Inflammatory and Immune Indices With Survival in Canine Patients With Oral Melanoma, Treated With Experimental Immunotherapy Alone or Experimental Immunotherapy Plus Metronomic Chemotherapy. <i>Frontiers in Veterinary Science</i> , 9,	3.1	0
3	Targeted Arginine Metabolism Therapy: A Dilemma in Glioma Treatment. <i>Frontiers in Oncology</i> , 12,	5.3	3
2	Replenishment of myeloid-derived suppressor cells (MDSCs) overrides CR-mediated protection against tumor growth in a murine model of triple-negative breast cancer.		
1	Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors [A phase I trial. 13,		1